

OTCQB Certification

I, Steve N. Slilaty, CEO of Sunshine Biopharma, Inc. ("the Company"), certify that:

1. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (mark the box below that applies with an "X"):
☐ Company is registered under Section 12(g) of the Exchange Act
☐ Company is relying on Exchange Act Rule 12g3-2(b)
☐ Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
☐ Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
☒ Company is reporting under Section 15(d) of the Exchange Act.
☐ Company is reporting under the Alternative Reporting Company Disclosure Guidelines
☐ Company is reporting under Regulation A (Tier 2)
☐ Other (describe) _____
2. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.
3. The Company Profile displayed on www.otcmarkets.com is current and complete as of March 31, 2021 and includes the total shares outstanding, authorized, and in the public float as of that date.
4. The share information below is for the primary OTCQB traded security as of the latest practicable date:

Trading Symbol		<u>SBFM</u>
The data in this chart is as of:		<u>March 31, 2021</u>
Shares Authorized	(A)	<u>3,000,000,000</u>
Total Shares Outstanding	(B)	<u>465,005,925</u>
Number of Restricted Shares (SEE NOTE 1 BELOW)	(C)	<u>11,154</u>
Unrestricted Shares Held by Officers, Directors, 10% Control Persons & Affiliates	(D)	<u>11,443,924</u>
Public Float: <i>Subtract Lines C and D from Line B</i>	(E)	<u>453,550,847</u>
% Public Float: <i>Line E Divided by Line B (as a %)</i> (SEE NOTE 2 BELOW)	(F)	<u>97.54%</u>
Number of Beneficial Shareholders of at least 100 shares (SEE NOTE 3 BELOW)	(G)	<u>147</u>

NOTE 1: Restricted Shares means securities that are subject to resale restrictions for any reason. Your transfer agent should be able to provide the total number of restricted securities.

NOTE 2: Public Float means the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "10 percent Control Person"), or any Affiliates thereof, or any Family Members of officers, directors and control persons. Family Member shall mean a Person's spouse, parents, children and siblings, whether by blood, marriage or adoption, or anyone residing in such Person's home. OTCQB traded securities are required to have a freely traded public float of at least 10% of the shares outstanding, unless an exemption applies.

NOTE 3: Beneficial Shareholder means any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security. OTCQB traded securities are required to have at least 50 beneficial shareholders, unless an exemption applies.

5. The company is duly organized, validly existing and in good standing under the laws of State of Colorado in which the Company is organized or does business.

6. The following is a complete list of any law firm(s) and attorney(s) that acted as the Company's primary legal counsel in preparing its most recent annual report. Include the firm and attorney(s) name if outside counsel, or name and title if internal counsel. (If no attorney assisted in putting together the disclosure, identify the person(s) who prepared the disclosure and their relationship to the company.) Please also identify any other attorney, if different than the primary legal counsel, that assisted the company during the prior fiscal year on any matter including but not limited to, preparation of disclosure, press releases, consulting services, corporate action or merger assistance, etc.

Mr. Andrew I. Telsey
6198 S. Moline Court
Englewood, CO 80111

7. The following is a complete list of third party providers, including names and addresses, engaged by the Company, its officers, directors or controlling shareholders, at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification, to provide investor relations services, public relations services, marketing, brand awareness, consulting, stock promotion, or any other related services to the Company. Please describe the services provided by each third party provider listed below.

None

8. Convertible Debt

The following is a complete list of all promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities that were issued or outstanding at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification:

☐ Check this box if there were no promissory notes, convertible notes, or other convertible debt arrangements issued or outstanding at any point during this time period.

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	Name of Noteholder (entities must have individual with voting / investment control disclosed). ¹	Reason for Issuance (e.g. Loan, Services, etc.)
Please see attached schedule								

Use the space below to provide any additional details, including footnotes to the table above:

¹ International Reporting Companies may elect not to disclose the names of noteholders who are non-affiliates of the company. "Affiliate" is a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, an officer, a director, or a shareholder beneficially-owning 10 percent or more of the Company's outstanding shares.

9. Officers, Directors and 5% Control Persons

The following is a complete list of Officers, Directors and 5% Control Persons (control persons are beneficial owners five percent (5%) or more of any class of the issuer's equity securities), including name, address, and number of shares owned. Options and warrants that can be converted into common shares within the next 60 days should be included in the shareholdings listed below. **If any of the beneficial shareholders are corporate entities, provide the name and address of the person(s) owning or controlling such corporate entities.**

Name	City and State (and Country if outside US)	Number of Shares Owned (list common, warrants and options separately)	Percentage of Class of Shares Owned
Dr. Steve N. Slilaty	Laval, Quebec, Canada	24,204,670 Common	5.21%
Camille Sebaaly	Montreal, Quebec, Canada	23,893,086 Common	5.14%
Dr. Abderrazzak Merzouki	Laval, Quebec, Canada	23,343,975 Common	5.02%
Dr. Steve N. Slilaty	Laval, Quebec, Canada	1,000,000 Series B Preferred	100%

10. Certification

Date: April 6, 2021

Name of Certifying CEO or CFO: Steve N. Slilaty

Title: CEO

Signature: /s/ Steve N. Slilaty

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

<<< Sunshine Biopharma Inc. >>>

<<< Convertible Debt Schedule As At March 31, 2021 >>>

DATE OF ISSUANCE	OUTSTANDING BALANCE	PRINCIPAL AMOUNT AT ISSUANCE	INTEREST RATE	INTEREST ACCRUED	MATURITY DATE	CONVERSION TERMS	# SHARES CONVERTED		NAME OF HOLDER	REASON FOR ISSUANCE
							TO DATE			
1-Apr-2017	\$0	\$74,970	9%	\$10,500	1-Apr-2019	\$0.011 Per Share Fixed	0		Rolland Veilleux	Operating Capital Loan
30-Nov-2019	\$0	\$43,559	8%	\$2,523	31-Aug-2020	35% Discount from market	14,198,048		GHS Investments (Sarfraz Hajee)	Operating Capital Loan
24-Dec-2018	\$0	\$87,000	8%	\$9,639	24-Dec-2019	35% Discount from market	43,986,317		GS Capital (Gabe Sayegh)	Operating Capital Loan
8-Jan-2019	\$0	\$54,000	8%	\$9,814	8-Jan-2020	35% Discount from market	44,931,640		GS Capital (Gabe Sayegh)	Operating Capital Loan
5-Feb-2019	\$0	\$37,450	8%	\$2,996	10-Oct-2019	35% Discount from market	38,263,409		Crown Bridge (Seth Ahdoot)	Operating Capital Loan
2-Jul-2019	\$0	\$40,000	8%	\$1,600	30-Apr-2020	35% Discount from market	13,099,359		Power Up (Curt Kramer)	Operating Capital Loan
26-Jul-2019	\$0	\$50,000	8%	\$4,909	26-Jul-2020	35% Discount from market	43,522,363		Black Ice (Brent Fouch)	Operating Capital Loan
12-Sep-2019	\$0	\$43,000	8%	\$1,720	15-Jul-2020	35% Discount from market	38,855,726		Power Up (Curt Kramer)	Operating Capital Loan
14-Dec-2019	\$0	\$42,800	8%	\$1,712	14-Dec-2020	35% Discount from market	18,592,605		Jefferson Street (Brian Goldberg)	Operating Capital Loan
31-Dec-2019	\$11,028	\$122,253	12%	\$14,017	31-Dec-2020	\$0.001 Per Share Fixed	121,000,000		RB Capital (Brett Rosen)	Operating Capital Loan
1-Jun-2020	\$0	\$42,000	8%	\$13,435	1-Jun-2021	35% Discount from market	0		Power Up (Curt Kramer)	Operating Capital Loan
9-Jun-2020	\$0	\$37,000	8%	\$11,779	9-Jun-2021	35% Discount from market	0		Power Up (Curt Kramer)	Operating Capital Loan
7-Jul-2020	\$0	\$48,000	8%	\$15,271	7-Jul-2021	35% Discount from market	0		Power Up (Curt Kramer)	Operating Capital Loan
27-Jul-2020	\$0	\$102,000	8%	\$4,171	27-Jul-2021	30% Discount from market	5,044,456		Jefferson Street (Brian Goldberg)	Operating Capital Loan
14-Aug-2020	\$0	\$67,000	8%	\$2,680	14-Aug-2021	30% Discount from market	542,173		Power Up (Curt Kramer)	Operating Capital Loan
14-Sep-2020	\$250,000	\$250,000	5%	\$6,771	14-Sep-2022	\$0.30 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan
24-Sep-2020	\$50,000	\$50,000	5%	\$1,271	24-Sep-2022	\$0.30 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan
20-Oct-2020	\$250,000	\$250,000	5%	\$5,521	20-Oct-2022	\$0.30 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan
19-Nov-2020	\$250,000	\$250,000	8%	\$7,167	19-Aug-2021	35% Discount from market	0		EMA (Byron Campo)	Operating Capital Loan
24-Nov-2020	\$260,000	\$260,000	8%	\$7,453	24-Nov-2021	30% Discount from market	0		GS Capital (Gabe Sayegh)	Operating Capital Loan
25-Nov-2020	\$250,000	\$250,000	5%	\$4,375	25-Nov-2022	\$0.30 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan
2-Dec-2020	\$104,215	\$104,215	5%	\$1,737	2-Dec-2022	\$0.30 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan
12-Jan-2021	\$150,000	\$150,000	5%	\$1,563	12-Jan-2023	\$0.60 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan
27-Jan-2021	\$300,000	\$300,000	5%	\$2,500	27-Jan-2023	\$0.50 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan
12-Feb-2021	\$700,000	\$700,000	5%	\$4,958	12-Feb-2023	\$0.60 Per Share Fixed	0		RB Capital (Brett Rosen)	Operating Capital Loan